




August 2026 Rush Research Newsletter: July 2026 New Award Recipients



- Grants are reported in the month of the project start date.
- Contracts and sub-awards are reported in the month the agreement is executed.


New Federal Awards

	Neelum T. Aggarwal, MD Alzheimer's Tau Platform (ATP) NIH - National Institute on Aging (NIA)
	Joseph Meschi, MD • NRG-GU008: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*), NIH - National Cancer Institute (NCI) • ANHL1931: A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma, NIH - National Cancer Institute (NCI) • E1A11: Randomized Ph III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic MM, National Cancer Institute (NCI) • EA3161: Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC, NIH - National Cancer Institute (NCI)
	Ryan Ross, PhD Impact of maternal integrase inhibitor use on offspring fat and bone development NIH - National Institute of Child Health and Human Development (NICHD)
	Nicole M. Russo-Ponsaran, PhD Early Elementary School Start Time: Impact on Sleep, Health, and Learning NIH - National Heart, Lung & Blood Institute (NHLBI)

New Non-Federal Awards

	Elizabeth M. Berry-Kravis, MD, PhD Development of Outcome Measures for Future Clinical Trials in Fragile X Syndrome Vertex Pharmaceuticals Inc.
	Jeffrey A. Borgia, PhD Collaboration with Tempus II - Retrospective xT testing of thoracic malignancies Tempus

	Jorge Chahla, MD Effect of Soft-Tissue Medial Meniscal Allograft Constructs on Tibiofemoral Contact Mechanics: A Cadaveric Study JRF Ortho
	Elaine Chen, MD RUMC CF Center Cystic Fibrosis Foundation (CFF)
	Alexander Cohen, MD D8991C00001/GOG-3127: Phase 3 Study of AZD5335 vs. Mirvetuximab Soravtansine in Fra-High and AZD5335 vs. Investigator's Choice Chemotherapy in Fra-Low Advanced High-Grade Platinum-Resistant Epithelial Ovarian Cancer (TREVI) AstraZeneca UK Limited
	R. Webster Crowley, MD Rapid Evacuation and Access of Cerebral Hemorrhage (REACH) Emory University
	Joshua Eloge, MD A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-Term Efficacy in Participants with Major Depressive Disorder (EXTEND) Cybin IRL Limited
	Alexander Mazur, MD (REPEAT-AF) Comparative Effectiveness of Different Techniques for Repeat Ablation After Failed Initial Ablation for Persistent Atrial Fibrillation Patient Centered Outcomes Research Institute (PCORI)
	Allison Osen, MD A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants with Bcell Mediated Autoimmune Disorders TG Therapeutics, Inc.
	John E. O'Toole, MD, MS DGx-A02 A Primary Prospective, Randomized, Double Blind, Sham-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of IDCT in Subjects with One-Level, Symptomatic Lumbar Intervertebral Disc Degeneration DiscGenics Inc.
	Nicole M. Russo-Ponsaran, PhD Evaluating the Feasibility Studying How School District Procurement Influence School District Use of Evidence in Selecting Instructional Resources William T. Grant Foundation
	Atsushi Sakuraba, MD - A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease, Sanofi US Services Inc. - A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis, Sanofi US Services Inc.

	Beverly E. Sha, MD Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion with Lenacapavir (LEN) Gilead Sciences Inc.
	Thomas Shoemaker, MD A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis Amgen
	Christina Swan, MD, PhD A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson's Disease (PD). (BHV8000-301) Biohaven Pharmaceuticals Inc.
	Nikhil Verma, MD Postoperative MRI Characterization of UCL Repair and Reconstruction Arthroscopy Association of North America (AANA)
	Thomas Westbrook, MD A Randomized Phase II Double-Blind Multicenter Study of Autogene Cevumeran Plus Nivolumab Versus Placebo Plus Nivolumab as Adjuvant Therapy in Patients with High-risk Muscle-invasive Urothelial Carcinoma (Protocol No BO45230) Hoffmann-La Roche Limited

To activate a [University Website Faculty Profile](#) complete the [University Faculty Profile Intake Form](#).